Gastrointestinal Cancer

Surufatinib improved progression-free survival compared with placebo in patients with low- or intermediate-grade advanced pancreatic neuroendocrine tumors for whom there is no effective therapy.

Afonso Ribeiro, MD, discusses the role of surgery in treating patients with pancreatic cancer.

The FDA has granted an orphan drug designation to durvalumab and tremelimumab for the treatment of patients with hepatocellular carcinoma.

Michael A. Choti, MD, discusses the future of treatment for patients with stage IV pancreatic cancer.

Josep Tabernero, MD, PHD, MSc, is best known for applying translational research against gastrointestinal tumors, with particular focus on colorectal cancer.

Therapeutic developments in cancer were rewarded with a wave of approvals in 2019.

Afonso Ribeiro, MD, medical director of Advanced Endoscopy and Gastroenterology at Memorial Healthcare System, discusses the criteria that can be used to determine whether a patient with pancreatic cancer is borderline resectable.

Investigators hope to answer a potentially paradigm-changing question in the phase II ANCHOR-CRC study (NCT03693170) of BRAF V600E–mutant colorectal cancer (CRC): Can the benefit observed with a targeted triplet in latestage disease extend to the first line?

Pablo Ferraro, MD, discusses the use of molecular profiling in pancreatic cancer.

Between 2013 and 2017, just 40% of patients with metastatic colon cancer received guideline-recommended biomarker testing that could have improved treatment decisions, according to findings from a retrospective study. Results also showed that adherence to evidence-based recommendations for genotyping was poor in academic and community settings alike.

Atif Hussein, MD, discusses the evolution treatment in hepatocellular carcinoma.

A. Craig Lockhart, MD, MHS, professor and associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses investigational strategies targeting the RAS/RAF/MEK/ERK pathway in colorectal cancer (CRC).

Atif Hussein, MD, discusses how the treatment of patients with hepatocellular carcinoma and cholangiocarcinoma has evolved in recent years.

The standard of care in the second line for patients with mismatch repair–deficient metastatic colorectal cancer has shifted to favor therapy utilizing immunotherapeutic agents, according to Howard Hochster, MD.

Yelena Y. Janjigian, MD, discusses the improvement in efficacy and toxicity with patients with hepatocellular carcinoma who are treated with bevacizumab and atezolizumab when compared with sorafenib.